Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

MLA

Graham, Jonathan, et al. “Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.” PharmacoEconomics, vol. 34, no. 8, Aug. 2016, pp. 815–27. EBSCOhost, https://doi.org/10.1007/s40273-016-0412-1.

APA

Graham, J., McBride, D., Stull, D., Halliday, A., Alexopoulos, S. T., Balp, M.-M., Griffiths, M., Agirrezabal, I., Zuberbier, T., & Brennan, A. (2016). Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. PharmacoEconomics, 34(8), 815–827. https://doi.org/10.1007/s40273-016-0412-1

Chicago

Graham, Jonathan, Doreen McBride, Donald Stull, Anna Halliday, Stamatia Theodora Alexopoulos, Maria-Magdalena Balp, Matthew Griffiths, Ion Agirrezabal, Torsten Zuberbier, and Alan Brennan. 2016. “Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.” PharmacoEconomics 34 (8): 815–27. doi:10.1007/s40273-016-0412-1.